MYD88 and lung carcinoma: Interestingly, the profound impact of rIL-33 on tumor immunity in the LLC lung cancer model was not replicated in MyD88-/- mice, underscoring the crucial role of the MyD88 pathway in mediating IL-33’s immunomodulatory effects.